Table 6. Summary of AEs.
| AEs | n (%) | |
| Ripertamab (N=42) | Rituximab* (N=42) | |
| AE, adverse event; TEAE, treatment emergent adverse event; TRAE, treatment-related adverse event; SAE, serious adverse event; IRR, infusion related reaction. *, Rituximab refers to MabThera®. | ||
| TEAEs | 33 (78.6) | 34 (81.0) |
| TRAEs | 21 (50.0) | 26 (61.9) |
| SAEs | 2 (4.8) | 1 (2.4) |
| Treatment discontinuation due to TEAEs | 1 (2.4) | 0 (0) |
| IRRs | 10 (23.8) | 10 (23.8) |
| TEAEs with incidence ≥5% in either group | ||
| Hematological toxicity | ||
| White blood cell count decreased |
2 (4.8) | 10 (23.8) |
| Neutrophil count decreased | 2 (4.8) | 8 (19.0) |
| Lymphocyte count decreased |
0 (0) | 3 (7.1) |
| Non-hematological toxicity | ||
| Pruritus | 4 (9.5) | 2 (4.8) |
| Upper respiratory tract infection |
3 (7.1) | 6 (14.3) |
| Alanine aminotransferase increased |
3 (7.1) | 3 (7.1) |
| Blood lactate dehydrogenase increased |
3 (7.1) | 1 (2.4) |
| Blood glucose increased | 3 (7.1) | 0 (0) |
| Urinary tract infection | 3 (7.1) | 0 (0) |
| Rash | 3 (7.1) | 0 (0) |
| Constipation | 3 (7.1) | 0 (0) |
| Insomnia | 3 (7.1) | 0 (0) |
| Hypersensitivity | 1 (2.4) | 6 (14.3) |
| Aspartate aminotransferase increased |
1 (2.4) | 4 (9.5) |